Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative ...

J&J has signed its latest Stelara patent settlement with Fresenius Kabi and Formycon, granting the biosimilar partners a U.S. license date for their drug beginning "no later than April 15, 2025," ...

Johnson & Johnson recently launched Stelara for the treatment of adult patients with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this ...

Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...

WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J ...